Membership Home Portfolio Stocks Options Funds ETFs CEFsnew Markets Tools Real Life Finance Discuss
Home>Topics>Stocks>Labopharm

Labopharm DDSS

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. UPDATE 1-Quebec court OKs Labopharm shareholder meeting

      Headlines

      Mon, 29 Aug 2011

      TORONTO, Aug 29 (Reuters) - A Quebec court authorized Labopharm Inc to hold a special meeting of shareholders for the approval of the Canadian biotech firm's acquisition by Paladin Labs .

    2. UPDATE 3-Paladin to buy biotech Labopharm in C$20 mln deal

      Headlines

      Wed, 17 Aug 2011

      * Labopharm shares jump 62 percent (Adds plans to eliminate a joint venture's sales force)

    3. UPDATE 2-Paladin to buy biotech Labopharm in C$20 mln deal

      Headlines

      Wed, 17 Aug 2011

      * Paladin has also made bid to buy Afexa Life Sciences (Adds details)

    4. UPDATE 1- Labopharm posts profit on licensing sales

      Headlines

      Thu, 4 Aug 2011

      TORONTO, Aug 4 (Reuters) - Canadian biotech company Labopharm Inc reported a quarterly profit from continuing operations on Thursday, compared with a loss a year ago.

    5. UPDATE 1- Labopharm posts bigger loss on costs from job cuts

      Headlines

      Wed, 4 May 2011

      TORONTO, May 4 (Reuters) - Canadian biotech Labopharm Inc , which is considering various strategic alternatives, posted a greater quarterly loss on Wednesday, hurt by costs associated with recent...

    6. UPDATE 1- Labopharm explores options, business combinations

      Headlines

      Fri, 29 Apr 2011

      TORONTO, April 29 (Reuters) - Canadian biotechnology firm Labopharm Inc said on Friday it was looking at various options for its assets and products, as well as exploring potential business...

    7. UPDATE 1- Labopharm trims workforce, names CFO

      Headlines

      Tue, 22 Mar 2011

      TORONTO, March 22 (Reuters) - Canadian biotech Labopharm Inc said on Tuesday it cut 38 jobs, a move that is expected to result in annual savings of $3.8 million, and named Sylvain Guenette chief financial officer.

    8. UPDATE 4- Labopharm antidepressant wins Canadian approval

      Headlines

      Thu, 20 Jan 2011

      * Shares rise as much as 19 percent (Adds CEO comment)

    9. Dropping Coverage of Labopharm

      Commentary

      Wed, 13 Jan 2010

      We are no longer providing equity research on Labopharm DDSS . We provide broad coverage of more than 1,800 companies across 91 industry groups, and adjust our coverage as necessary based on client demand and investor interest.

    10. Labopharm Awaits Trazodone Approval

      Commentary

      Tue, 15 Dec 2009

      Labopharm DDSS shareholders await a major binary event ..... approved, trazodone could transform Labopharm into a profitable company as early as ..... The chances of approval are good since Labopharm resolved its active ingredient manufacturing …

    « Prev123Next »

    Hot Topics

    1. Signet Jewelers
    2. Toro Company
    3. B&G Foods
    4. Wall Street
    5. Emerging Markets
    Content Partners
    Site Directory Site Map Our Products
    Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
    International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K.
    Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

    © Copyright 2010 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. Russell 2000 quote is 10 minutes delayed.